Based in Oslo, Norway, Lytix Biopharma is a clinical stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic peptide with the potential to personalize immunotherapy.
LTX-315 is administered intratumorally and works by inducing lysis of intracellular organelles of tumor cells such as mitochondria, thereby unleashing a broad spectrum of tumor antigens for T cell responses. LTX-315 effectively kills not only therapy tumor cells, but also therapy resistant and stem cell-like tumor cells, invoking broad personal T cell responses, in both the tumor and blood. Clinical trials have shown an increase in CD8+ T cell infiltration and clinical abscopal effects. The company strategy is to utilize this T cell response as a primer to enhance and boost patient specific and tumor associated antigens as part of an adoptive transfer regimen aiming to tackle tumor heterogeneity.